Swissmedic approves Buvidal for the treatment of opioid dependence
LUND, Sweden, Dec. 18, 2020 /PRNewswire/ Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. This marks the first approval of a long-acting treatment for opioid dependence in Switzerland. We are pleased with the expeditious review and approval of our market authorization application for Buvidal by Swissmedic and that patients with opioid dependence in Switzerland will now have access to an effective long-acting treatment, says Fredrik Tiberg, PhD, President & CEO of Camurus.